

Disorders Tested

Exon Panel

CLINICAL IMPACT AREAS

● Life Expectancy	Decreased life expectancy and increased childhood mortality
● Quality of Life	Severe impact on quality of life; typically no effect on life expectancy
● Treatment Benefits	Early medical intervention can increase life expectancy or reduce symptoms
● Intellectual Ability	Associated with varying degrees of intellectual disability

	Life Expectancy	Quality of Life	Treatment Benefits	Intellectual Ability		Life Expectancy	Quality of Life	Treatment Benefits	Intellectual Ability
					Chronic granulomatous disease (X-linked)*		●	●	
					Citrin deficiency		●	●	
					Citrullinemia, type I	●		●	
					Combined pituitary hormone deficiency, PROP1-related		●	●	
					Congenital amegakaryocytic thrombocytopenia	●			
					Congenital disorder of glycosylation, type IA	●			●
					Congenital disorder of glycosylation, type IB	●		●	
					Congenital myasthenic syndrome, CHAT-related		●	●	
					Congenital myasthenic syndrome, CHRNE-related		●	●	
					Congenital myasthenic syndrome, RAPSN-related		●	●	
					Crigler-Najjar syndrome	●		●	●
					Cystic fibrosis†	●			
					Cystinosis†		●		
					D-bifunctional protein deficiency	●			
					Dihydroliipoamide dehydrogenase deficiency	●		●	●
					Dihydropyrimidine dehydrogenase deficiency	●		●	●
					Duchenne/Becker muscular dystrophy (X-linked)*†	●			
					Dyskeratosis congenita, RTEL1-related	●			
					Ehlers Danlos syndrome, type VIIC		●		
					Ethylmalonic encephalopathy	●		●	
					Familial dysautonomia	●			
					Familial hyperinsulinism, ABCC8-related		●		
					Fanconi anemia, type C	●		●	●
					Fetal akinesia deformation sequence, DOK7-related		●		
					Fragile X syndrome (X-linked)*		●		●
					Fumarase deficiency	●			●
					Galactosemia†	●		●	●
					Gaucher disease	●		●	
					Glucose-6-phosphate dehydrogenase deficiency (X-linked)*		●	●	
					Glutaric acidemia, type I	●		●	●
					Glycine encephalopathy, AMT-related	●			●
					Glycine encephalopathy, GLDC-related	●			●
					Glycogen storage disease, type IA	●		●	
					Glycogen storage disease, type IB	●		●	
					Glycogen storage disease, type II	●		●	
					Glycogen storage disease, type III	●		●	
					GM1-gangliosidosis	●			●
					GRACILE syndrome	●			
					Hereditary fructose intolerance		●	●	
					Hermansky-Pudlak syndrome, type III	●			

	Life Expectancy	Quality of Life	Treatment Benefits	Intellectual Ability		Life Expectancy	Quality of Life	Treatment Benefits	Intellectual Ability
Homocystinuria, CBS-related	●		●	●	Niemann-Pick disease, type C1	●			●
Hypophosphatasia, autosomal recessive	●				Nijmegen breakage syndrome	●			●
Inclusion body myopathy, type II		●			Nonsyndromic hearing loss, GJB2-related		●	●	
Infantile neuroaxonal dystrophy, type 1	●			●	Nonsyndromic hearing loss, GJB6-related†		●	●	
Isovaleric acidemia	●		●		Omenn syndrome	●		●	
Joubert syndrome 2	●			●	Ornithine transcarbamylase deficiency (X-linked)*	●		●	●
Junctional epidermolysis bullosa, LAMA3-related	●				Ornithine translocase deficiency	●		●	●
Junctional epidermolysis bullosa, LAMB3-related	●				Pendred syndrome			●	
Junctional epidermolysis bullosa, LAMC2-related	●				Phenylalanine hydroxylase deficiency			●	●
Juvenile nephronophthisis, type 1†		●		●	POLG-related disorders	●			●
Krabbe disease†	●		●		Primary carnitine deficiency		●	●	
Lamellar ichthyosis, type I		●			Primary congenital glaucoma			●	
Leigh syndrome, French Canadian	●			●	Primary hyperoxaluria, type I	●		●	
Leukoencephalopathy with vanishing white matter	●			●	Primary hyperoxaluria, type II	●		●	
Limb-girdle muscular dystrophy, type 2A	●	●			Propionic acidemia, PCCA-related	●		●	●
Limb-girdle muscular dystrophy, type 2C		●			Propionic acidemia, PCCB-related	●		●	●
Limb-girdle muscular dystrophy, type 2D		●			Pycnodysostosis		●		
Limb-girdle muscular dystrophy, type 2E		●			Pyruvate carboxylase deficiency	●			●
Long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency	●		●	●	Retinitis pigmentosa 59		●		
Lowe syndrome (X-linked)*	●			●	Rhizomelic chondrodysplasia punctata, type I	●			●
Lysinuric protein intolerance			●	●	Salla disease	●			●
Maple syrup urine disease, type IA	●		●	●	Sandhoff disease	●			●
Maple syrup urine disease, type IB	●		●	●	Severe combined immunodeficiency, IL2RG-related (X-linked)*	●		●	
Maple syrup urine disease, type II	●		●	●	Sjögren-Larsson syndrome	●			●
MECP2 duplication syndrome (X-linked)*†	●			●	Smith-Lemli-Opitz syndrome	●		●	●
Medium-chain acyl-CoA dehydrogenase deficiency	●		●	●	Spastic ataxia of Charlevoix-Saguenay (ARSACS)	●			
Megalencephalic leukoencephalopathy with subcortical cysts, type I		●		●	Spinal muscular atrophy†	●		●	
Metachromatic leukodystrophy	●			●	Steroid-resistant nephrotic syndrome	●			
Methylmalonic aciduria, cblC type	●		●	●	Sulfate transporter-related osteochondrodysplasia	●			
Mucopolipidosis type IV†		●		●	Tay-Sachs disease†	●			●
Mucopolipidosis, type II/III alpha/beta	●			●	Tyrosine hydroxylase deficiency		●	●	●
Mucopolysaccharidosis type IIIA (Sanfilippo A)	●			●	Tyrosinemia, type I	●		●	
Mucopolysaccharidosis, type I-Hurler syndrome	●		●	●	Usher syndrome, type IB		●	●	
Multiple sulfatase deficiency	●			●	Usher syndrome, type IC		●	●	
Muscle-eye-brain disease	●			●	Usher syndrome, type ID		●	●	
Nemaline myopathy 2†	●				Usher syndrome, type IF		●	●	
Nephrotic syndrome, type I	●				Usher syndrome, type IIA		●	●	
Neuronal ceroid lipofuscinosis, CLN3-related†	●			●	Usher syndrome, type III		●	●	
Neuronal ceroid lipofuscinosis, CLN5-related	●			●	Very long-chain acyl-CoA dehydrogenase deficiency	●		●	
Neuronal ceroid lipofuscinosis, CLN6-related	●			●	Walker-Warburg syndrome	●			●
Neuronal ceroid lipofuscinosis, CLN8-related	●			●	Wilson disease	●		●	
Neuronal ceroid lipofuscinosis, PPT1-related	●			●	Wiskott-Aldrich syndrome (X-linked)*	●		●	
Neuronal ceroid lipofuscinosis, TPP1-related	●			●	Zellweger spectrum disorders, PEX1-related	●			●
Niemann-Pick disease, type A and B	●			●	Zellweger spectrum disorders, PEX2-related	●			●

For more information, visit progenity.com/preparent

5230 S. State Road, Ann Arbor, MI 48108 USA • Tel +1 855-293-2639 • progenity.com

* Carrier testing for X-linked disorders is not performed in males. † CNV analysis is clinically relevant and performed for select disorders.

Progenity, Inc. is a CLIA-certified clinical laboratory and is accredited by the College of American Pathologists (CAP). ©2019 Progenity, Inc. All rights reserved. Progenity® and Preparent® are registered service marks of Progenity, Inc. WH-48014-01 REV 082019